Literature DB >> 26492928

Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?

Mike P Wattjes1, Clemens Warnke2.   

Abstract

Entities:  

Keywords:  MRI; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY

Mesh：

Substances：

Year:  2015        PMID： 26492928     DOI： 10.1136/jnnp-2015-311386

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

Review 1.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

3.  Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).

Authors:  Tjalf Ziemssen; Ulrich Engelmann; Sigbert Jahn; Alexandra Leptich; Raimar Kern; Lina Hassoun; Katja Thomas
Journal:  BMC Neurol       Date:  2016-07-19       Impact factor: 2.474

4.  High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis.

Authors:  Alexander Lau; Wei Qiu; Allan Kermode; Cheryl Au; Angel Ng; Adrian Wong; Sze-Ho Ma; Lisa Au; Karen Ma; Bonaventure Ip; Vincent Mok
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.